OncoLink en espanõl
Share
Cancer Resources > Cancer News > Cancer News from Reuters > Reuters Cancer News > 2008 > September
Raloxifene reduces risk of endometrial cancer
David Douglas
Last Updated: 2008-09-25 8:30:40 -0400 (Reuters Health)
NEW YORK (Reuters Health) - While raloxifene and tamoxifen are broadly similar in reducing breast cancer risk, raloxifene also appears to lower the odds of developing endometrial cancer, researchers report in the September 1st issue of the Journal of Clinical Oncology.
"These data are important," lead investigator Dr. Angela DeMichele told Reuters Health, "because they suggest a critical difference between tamoxifen and raloxifene that could help physicians in tailoring therapy to the patient."
She added, "A randomized clinical trial has shown that the drugs are roughly equivalent in terms of their ability to prevent breast cancer."
To examine the effect of raloxifene and tamoxifen on endometrial cancer risk, Dr. DeMichele of the University of Pennsylvania, Philadelphia, and colleagues examined data on 547 women who were diagnosed with endometrial cancer and 1410 controls.
Some 3.3% of the cases had taken raloxifene compared to 6.6% of the controls. Corresponding proportions for tamoxifen were 6.2% and 2.4%.
After adjustment for other risk factors, the risk of endometrial cancer in raloxifene users was half that of nonusers (odds ratio = 0.50). Tamoxifen users were three times more likely to develop endometrial cancer than were raloxifene users (odds ratio = 3.0).
Overall, raloxifene users were at significantly reduced risk of endometrial cancer compared to both tamoxifen users and women who did not use a selective estrogen receptor modulator.
Given the similarity in protection against breast cancer, continued Dr. DeMichele, "a secondary benefit, like a reduction in the risk of endometrial cancer, may be very important to patients who have not had a hysterectomy and are concerned about the increased risk of endometrial cancer with tamoxifen."
J Clin Oncol 2008;26:4151-4159.
Copyright © 2009 Reuters Limited. All rights reserved.
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.